Jonathan A. Pachter

6.3k total citations · 1 hit paper
137 papers, 4.4k citations indexed

About

Jonathan A. Pachter is a scholar working on Molecular Biology, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jonathan A. Pachter has authored 137 papers receiving a total of 4.4k indexed citations (citations by other indexed papers that have themselves been cited), including 71 papers in Molecular Biology, 57 papers in Oncology and 21 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jonathan A. Pachter's work include Cell Adhesion Molecules Research (21 papers), Chronic Lymphocytic Leukemia Research (17 papers) and PI3K/AKT/mTOR signaling in cancer (17 papers). Jonathan A. Pachter is often cited by papers focused on Cell Adhesion Molecules Research (21 papers), Chronic Lymphocytic Leukemia Research (17 papers) and PI3K/AKT/mTOR signaling in cancer (17 papers). Jonathan A. Pachter collaborates with scholars based in United States, United Kingdom and Italy. Jonathan A. Pachter's co-authors include David T. Weaver, Irina M. Shapiro, Samarth Hegde, Brett L. Knolhoff, David G. DeNardo, Hong Jiang, William G. Hawkins, Andrea Wang‐Gillam, Yu Zhu and Melissa A. Meyer and has published in prestigious journals such as Cell, Proceedings of the National Academy of Sciences and Journal of Biological Chemistry.

In The Last Decade

Jonathan A. Pachter

129 papers receiving 4.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Targeting focal adhesion kinase renders pancreatic cancers responsive to checkpoint immunotherapy

2016 754 citations Irina M. Shapiro, David T. Weaver et al. profile →

Peers

Countries citing papers authored by Jonathan A. Pachter

Since Specialization

Citations

This map shows the geographic impact of Jonathan A. Pachter's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jonathan A. Pachter with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jonathan A. Pachter more than expected).

Fields of papers citing papers by Jonathan A. Pachter

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jonathan A. Pachter. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jonathan A. Pachter. The network helps show where Jonathan A. Pachter may publish in the future.

Co-authorship network of co-authors of Jonathan A. Pachter

This figure shows the co-authorship network connecting the top 25 collaborators of Jonathan A. Pachter. A scholar is included among the top collaborators of Jonathan A. Pachter based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jonathan A. Pachter. Jonathan A. Pachter is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preclinical Efficacy of the Estrogen Receptor Degrader Fulvestrant in Combination with RAF/MEK Clamp Avutometinib and FAK Inhibitor in a Low-Grade Serous Ovarian Cancer Animal Model with Acquired Resistance to Chemotherapy and Aromatase Inhibitor 2025 ·International Journal of Molecular Sciences ·(unknown), Stefania Bellone, (unknown), (unknown), Tobias M.P. Hartwich, Blair McNamara, (unknown), Yang Yang‐Hartwich, Elena Ratner, (unknown), (unknown), (unknown), (unknown), Jonathan A. Pachter, (unknown), Alessandro D. Santin	0
2	Avutometinib/defactinib and gemcitabine/nab-paclitaxel combination in first-line metastatic pancreatic ductal adenocarcinoma: Initial safety and efficacy of phase 1b/2 study (RAMP 205). 2024 ·Journal of Clinical Oncology ·Kian‐Huat Lim, Kristen Spencer, Rachael A. Safyan, Vincent J. Picozzi, Anna M. Varghese, Despina Siolas, Kimberly Perez, (unknown), (unknown), Vijeta Bhambhani, (unknown), Jonathan A. Pachter, Philippe Pultar, Manuel Hidalgo	9
3	Roles of PI3Kγ and PI3Kδ in mantle cell lymphoma proliferation and migration contributing to efficacy of the PI3Kγ/δ inhibitor duvelisib 2023 ·Scientific Reports ·Kathleen J. Till, (unknown), (unknown), (unknown), Thomas A. Marks, Sílvia Coma, David T. Weaver, Jonathan A. Pachter, Andrew R. Pettitt, Joseph R. Slupsky	5
4	Duvelisib Eliminates CLL B Cells, Impairs CLL-Supporting Cells, and Overcomes Ibrutinib Resistance in a Xenograft Model 2023 ·Clinical Cancer Research ·Shih‐Shih Chen, Jacqueline C. Barrientos, Gerardo Ferrer, (unknown), (unknown), (unknown), Michael Ibrahim, (unknown), (unknown), Jeffery L. Kutok, (unknown), (unknown), David T. Weaver, Jonathan A. Pachter, R. Kanti, Nicholas Chiorazzi	5
5	PI3Kδ/γ inhibition promotes human CART cell epigenetic and metabolic reprogramming to enhance antitumor cytotoxicity 2022 ·Blood ·(unknown), (unknown), (unknown), (unknown), Aditi Sharma, (unknown), Vikas A. Gupta, Shanmuganathan Chandrakasan, Jaquelyn T. Zoine, Andrew Fedanov, Sunil S. Raikar, Jean L. Koff, Christopher R. Flowers, Sílvia Coma, Jonathan A. Pachter, Sruthi Ravindranathan, H. Trent Spencer, Mala Shanmugam, Edmund K. Waller	91
6	FAK inhibition alone or in combination with adjuvant therapies reduces cancer stem cell activity 2021 ·npj Breast Cancer ·S Timbrell, (unknown), Angela Cramer, (unknown), David T. Weaver, Jonathan A. Pachter, (unknown), Robert B. Clarke, Gillian Farnie, Nigel Bundred	22
7	Synthetic Lethal Screens Reveal Cotargeting FAK and MEK as a Multimodal Precision Therapy for GNAQ -Driven Uveal Melanoma 2021 ·Clinical Cancer Research ·Justine S. Paradis, (unknown), Robert Saddawi‐Konefka, (unknown), Simone Lubrano, (unknown), Nadia Arang, Manoela Tiago, Sílvia Coma, Xingyu Wu, Kyle Ford, Chi‐Ping Day, Glenn Merlino, Prashant Mali, Jonathan A. Pachter, Takami Sato, Andrew E. Aplin, J. Silvio Gutkind	54
8	Combinatorial Inhibition of Focal Adhesion Kinase and BCL-2 Enhances Antileukemia Activity of Venetoclax in Acute Myeloid Leukemia 2020 ·Molecular Cancer Therapeutics ·Xiangmeng Wang, Po Yee Mak, Hong Mu, Wenjing Tao, Arvind Rao, Visweswaran Ravikumar, Vivian Ruvolo, Jonathan A. Pachter, David T. Weaver, Michael Andreeff, Bing Xu, Bing Z. Carter	13
9	Focal Adhesion Kinase as a Potential Target in AML and MDS 2017 ·Molecular Cancer Therapeutics ·Bing Z. Carter, Po Yee Mak, Xiangmeng Wang, Hui Yang, Guillermo Garcia‐Manero, Duncan H. Mak, Hong Mu, Vivian Ruvolo, Yihua Qiu, Kevin R. Coombes, Nianxiang Zhang, Brittany Knick Ragon, David T. Weaver, Jonathan A. Pachter, Steven M. Kornblau, Michael Andreeff	31
10	PI3K/mTOR Dual Inhibitor VS-5584 Preferentially Targets Cancer Stem Cells 2014 ·Cancer Research ·Vihren N. Kolev, Quentin G. Wright, Christian M. Vidal, Jennifer E. Ring, Irina M. Shapiro, Jill M. Ricono, David T. Weaver, Mahesh V. Padval, Jonathan A. Pachter, Qunli Xu	116
11	Tumor Suppressor Alterations Cooperate to Drive Aggressive Mesotheliomas with Enriched Cancer Stem Cells via a p53–miR-34a–c-Met Axis 2013 ·Cancer Research ·Craig W. Menges, Yuwaraj Kadariya, Deborah A. Altomare, Jacqueline Talarchek, (unknown), Yue Wu, Guang‐Hui Xiao, Irina M. Shapiro, Vihren N. Kolev, Jonathan A. Pachter, Andres J. Klein–Szanto, Joseph R. Testa	47
12	ROCK1 and ROCK2 Are Required for Non-Small Cell Lung Cancer Anchorage-Independent Growth and Invasion 2012 ·Cancer Research ·Dominico Vigil, Tai Young Kim, (unknown), Andrew J. Garton, (unknown), Jonathan A. Pachter, Hanqing Dong, Xin Chen, (unknown), Sharon L. Campbell, Channing J. Der	109
13	Preclinical Characterization of OSI-027, a Potent and Selective Inhibitor of mTORC1 and mTORC2: Distinct from Rapamycin 2011 ·Molecular Cancer Therapeutics ·Shripad V. Bhagwat, Prafulla C. Gokhale, Andrew P. Crew, (unknown), Yan Yao, Christine Mantis, Jennifer Kahler, (unknown), Mark Bittner, Lorina Dudkin, David Epstein, Neil W. Gibson, Robert Wild, Lee D. Arnold, Peter J. Houghton, Jonathan A. Pachter	159
14	A Fully Human Insulin-Like Growth Factor-I Receptor Antibody SCH 717454 (Robatumumab) Has Antitumor Activity as a Single Agent and in Combination with Cytotoxics in Pediatric Tumor Xenografts 2010 ·Molecular Cancer Therapeutics ·Yaolin Wang, Philip Lipari, Xiaoying Wang, (unknown), Lianzhu Liang, Robert Ramos, Ming Liu, Jonathan A. Pachter, W. Robert Bishop, Yan Wang	39
15	Compensatory Insulin Receptor (IR) Activation on Inhibition of Insulin-Like Growth Factor-1 Receptor (IGF-1R): Rationale for Cotargeting IGF-1R and IR in Cancer 2010 ·Molecular Cancer Therapeutics ·Elizabeth Buck, Prafulla C. Gokhale, Susan Koujak, Eric Brown, Alexandra Eyzaguirre, Nianjun Tao, Maryland Rosenfeld-Franklin, Lorena Lerner, M. Isabel Chiu, Robert Wild, David Epstein, Jonathan A. Pachter, Mark Miglarese	183
16	High-Throughput Screening for mTORC1/mTORC2 Kinase Inhibitors Using a Chemiluminescence-Based ELISA Assay 2009 ·Assay and Drug Development Technologies ·Shripad V. Bhagwat, Jennifer Kahler, Yan Yao, (unknown), (unknown), (unknown), Michael D. Boisclair, Jonathan A. Pachter	5
17	Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors 2008 ·Cancer Research ·Elizabeth Buck, Alexandra Eyzaguirre, Maryland Rosenfeld-Franklin, Stuart Thomson, Mark J. Mulvihill, Sharon Barr, Eric Brown, (unknown), Yan Yao, Jonathan A. Pachter, Mark Miglarese, David Epstein, Kenneth K. Iwata, John D. Haley, Neil W. Gibson, Qunsheng Ji	164
18	A novel, potent, and selective insulin-like growth factor-I receptor kinase inhibitor blocks insulin-like growth factor-I receptor signaling in vitro and inhibits insulin-like growth factor-I receptor–dependent tumor growth in vivo 2007 ·Molecular Cancer Therapeutics ·Qunsheng Ji, Mark J. Mulvihill, Maryland Rosenfeld-Franklin, Andrew Cooke, Lixin Feng, (unknown), Matthew O’Connor, Yan Yao, Caroline Pirritt, Elizabeth Buck, Alexandra Eyzaguirre, Lee D. Arnold, Neil W. Gibson, Jonathan A. Pachter	118
19	Inhibition of IGF-1R by OSI-906 potentiates efficacy of various molecular targeted agents by blocking feedback loops converging at the level of IRS-1 2007 ·Molecular Cancer Therapeutics ·Elizabeth Buck, Alexandra Eyzaguirre, Maryland Rosenfeld-Franklin, Sharon Barr, Jonathan A. Pachter, Kenneth K. Iwata, John D. Haley, Neil W. Gibson, Qunsheng Ji	1
20	Preclinical characterization of OSI-906: A novel IGF-1R kinase inhibitor in clinical trials 2007 ·Molecular Cancer Therapeutics ·Qunsheng Ji, Mark J. Mulvihill, Maryland Rosenfeld-Franklin, Elizabeth Buck, Andrew Cooke, Alexandra Eyzaguirre, (unknown), Matthew O’Connor, Caroline Pirritt, Yan Yao, Neil W. Gibson, Jonathan A. Pachter	4

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact